Briacell Therapeutics Corp BCTX

$3.77 -0.18 (-4.56%)

Valuation

Market cap
34,493,000
Revenue TTM
$0
Net income TTM
$-26,310,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
64,363
Avg volume
108,136
Day's range
$3.65 – $3.99
Shares out
8,732,000
Stochastic %K
89%
Beta
1.26
Analysts
—
Price target
$40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...

Show more

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. The company is headquartered in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604-921-1810
Website
https://briacell.com
Address
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news

Stocktwits

docone Nov 9, 1:39 AM
$BCTX try a billion on MC minimum
0 replies
Orlandotrader Nov 8, 5:11 PM
$BCTX 8 Million Shares with fully Diluted at 15 Million Shares. Positive phase 3 Brings 150-300 Million MC per Gemini. Definitely gonna be a Binary Event due to the Paultry MC of 60 Million fully diluted. Let’s remember how we got here: Massively underfunded Bio which had to do many small equity raises that was destroyed by Short Sellers causing Many Reverse Splits and Shareholders Equity Destruction. They were finally able to Engineer a 30 Million Dollar Equity raise several months ago. Hopefully this will be the Exception. Feuerstein-Ratain (F-R) Rule, which predicts the Phase 3 clinical trial outcomes of small-cap biotech companies. It was formulated by veteran biotech journalist Adam Feuerstein and Dr. Mark Ratain, an oncologist at the University of Chicago. The Core Rule If a public biotechnology company has a market capitalization of $300 million or less exactly four months before a Phase 3 oncology trial readout, the trial will fail.
3 replies
AliceFireSteam Nov 8, 3:40 PM
$BCTX 7000 shares, let's go!
0 replies
smallpower17 Nov 6, 9:39 PM
$BCTX But what if it actually works?
2 replies
BCTX20bMC Nov 6, 8:43 PM
$BCTX wrong again. 🌋
1 replies
Orlandotrader Nov 6, 8:35 PM
$BCTX Nice Run
0 replies
BHWinehouse Nov 6, 8:00 PM
$BCTX Are we are entering FOMO Fridays?
0 replies
CoffeeRocks Nov 6, 7:48 PM
$OBX $IOVA $VKTX $BCTX $LPCN OBX 5$ 50% up from 9.5$S
0 replies